Loading
Neogenomics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Aug 2025.
Neogenomics Inc: what insiders have been doing
Every trade that managers of Neogenomics Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Fort Myers, United States. It was founded in 2002. From 18 October 2025 to 18 October 2026, the disclosure feed for Neogenomics Inc logged 29 filings by 8 insiders.
No insider bought on the market over the period, while 3 insiders filed 3 sales totalling €559k. Biggest ticket of the year: €279k, sold by Aunan Greg D and made public on 6 August 2026 (0.013% of market cap).
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 29 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at 10 purchases and 13 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 727.3 m USD and net income at -108.0 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
170
Thresholds
n/a
Buy Volume
€1M
10 ops. · all time
Sell Volume
€8M
13 ops. · all time
Who traded when
BuySaleAlicia C. Olivo2 sales
Anthony P. Zook2 buys
Jeffrey Scott Sherman2 buys
Greg D. Aunan1 sale
Gunn Neil1 buy
Kanovsky Stephen M1 buy
+4 other insiders
Since the insiders bought
- +187.7%Entry US$5.76 · Close at T+365 US$16.57
- +187.7%Entry US$5.76 · Close at T+365 US$16.57
- +42.7%Entry US$7.37 · Close at T+365 US$10.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Neogenomics Inc Buy (bullish), based on 10 analysts. Average price target: US$21.85.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,786 of 24,148 companies
29.3
score / 100
Value27
Quality31
FCF yld-1.0%
Earn yld-4.8%
EV/EBITDA·
ROE-6.3%
Gross mgn43%
Net mgn-15%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.66
Analyst consensus
10 analystsBuy
US$16.50Target US$21.85(+31%)US$35.00
Income statement
RevenueUS$727.3M
Gross profitUS$314.3M43% margin
EBITDA-US$38.7M-5% margin
Net income-US$108M-6.8% margin
Valuation
PER (forward)48.6x
P/Book2.7x
Beta1.78
Balance sheet & cash
Market capUS$2.2B
Total debtUS$409.5M
Free Cash Flow-US$21.8M
Debt / Equity57%
Profitability & ownership
ROE-6.3%
ROA-1.9%
% insiders2.1%
% institutions115.2%
Last declaration on 5 October 2026
Declarations170 total
17,562 shares0Common StockSEC:0001628280-26-064959:0
6,911 shares0Common StockSEC:0001628280-26-064959:1
2,692 shares0Common StockSEC:0001628280-26-060499:0
28,106 shares0Common StockSEC:0001628280-26-058913:0
11,060 shares0Common StockSEC:0001628280-26-058913:1
20,000 shares@ US$16.070.013% mcap100.0% of flowCommon StockSEC:0001646370-26-000002:0
20,000 shares@ US$16.0740.019% mcap100.0% of flowCommonSEC144:0001950047-26-007613
236,876 shares@ US$15.63920.22% mcap100.0% of flowCommonSEC144:0001950047-26-007427
5,307 shares@ US$11.15100.0% of flowCommonSEC144:0001950047-26-006094
5,307 shares@ US$10.950.0031% mcap100.0% of flowCommonSEC144:0001950047-26-005824
3,944 shares0Common StockSEC:0001628280-26-034620:0
937 shares0Common StockSEC:0001628280-26-030622:0
5,372 shares0Common StockSEC:0001628280-26-030622:1
1,309 shares0Common StockSEC:0001628280-26-030622:2
140,498 shares0Common StockSEC:0001628280-26-023689:0
45,453 shares0Common StockSEC:0001628280-26-023689:1
17,562 shares0Common StockSEC:0001628280-26-023691:0
6,911 shares0Common StockSEC:0001628280-26-023691:1
28,105 shares0Common StockSEC:0001628280-26-011102:0
42,158 shares0Common StockSEC:0001628280-26-011099:0
21,079 shares0Common StockSEC:0001628280-26-011097:0
6,323 shares0Common StockSEC:0001628280-26-011095:0
22,128 shares@ US$12.5037100.0% of flowCommon StockSEC:0001628280-26-002970:0
59,382 shares0Common StockSEC:0001628280-26-002199:0
59,382 shares0Common StockSEC:0001628280-26-002198:0
25 of 170 declarations
About Neogenomics Inc
NeoGenomics, Inc. is a U.S.-listed oncology diagnostics company traded on the NASDAQ in the United States. Headquartered in Fort Myers, Florida, the group is focused on cancer genetics testing, pathology support, and precision-medicine solutions for oncologists, pathologists, hospitals, academic centers, and pharmaceutical partners. Its business model combines laboratory testing, advanced molecular diagnostics, and consultative services, making it one of the more specialized names in the oncology diagnostics space.
Founded in the early 2000s, NeoGenomics has evolved from a regional laboratory operator into a broader oncology diagnostics platform with a nationwide footprint. In 2024, management simplified the operating structure into a single integrated segment, bringing Clinical Services and Advanced Diagnostics together. That move reflects a clearer commercial strategy and a stronger focus on operating efficiency, cross-selling, and end-to-end cancer testing workflows. The company’s menu includes cytogenetics, histopathology, molecular diagnostics, next-generation sequencing (NGS), biomarker testing, and therapy-selection tools designed to support diagnosis, treatment planning, and disease monitoring.
Read moreShow less
From a competitive standpoint, NeoGenomics operates in a market that is both attractive and highly contested. It competes with large reference laboratories, molecular diagnostics companies, and specialized oncology testing providers. Its competitive edge lies in deep oncology specialization, a broad and clinically relevant test portfolio, medical interpretation capabilities, and a data-driven approach to precision medicine. The company is also notable for its geographic reach: it operates CAP-accredited and CLIA-certified laboratories across several U.S. locations, with an additional laboratory presence in Cambridge, United Kingdom. That footprint supports national service coverage and gives the company flexibility in sample processing and clinical support.
Recent developments underscore NeoGenomics’ push toward higher-value, innovation-led growth. In the first quarter of 2026, the company reported 11% year-over-year revenue growth, led by 14% growth in Clinical revenue, and raised its full-year 2026 revenue guidance. Management also highlighted the launch of RaDaR ST, a ctDNA assay for molecular residual disease detection, along with a favorable MolDX coverage decision for PanTracer LBx and the introduction of PanTracer Pro. These initiatives strengthen the company’s oncology precision-testing platform and expand its addressable market in advanced cancer diagnostics.
For investors, NeoGenomics is a U.S. NASDAQ-listed healthcare diagnostics company with a focused oncology franchise, improving operating momentum, and a product pipeline aimed at capturing secular growth in molecular testing and precision oncology.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
